Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EEF2 | P13639 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12090565 | 0.87 | EEF2K (0.49) | EEF2KCTSKTDP1PDE5APDE4A | |
| SCHEMBL1108636 | 0.82 | EEF2K (0.43) | EEF2KCTSKTDP1PDE5APDE4A | |
| SCHEMBL1108632 | 0.79 | EEF2K (0.46) | EEF2KCTSKTDP1PDE5APDE4A | |
| SCHEMBL1061386 | 0.77 | ALDH1A1 (0.51) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL1108630 | 0.76 | EEF2K (0.51) | EEF2KCTSKPDE5APDE4APDE4B | |
| SCHEMBL1108631 | 0.76 | EEF2K (0.48) | EEF2KCTSKPDE5APDE4APDE4B | |
| SCHEMBL12090721 | 0.76 | EEF2K (0.46) | EEF2KCTSKTDP1PDE5APDE4A | |
| Hydrochloric Acid SCHEMBL1565880 | 0.75 | ALDH1A1 (0.50) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7321782 | 0.75 | ADORA2A (0.46) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9427515 | 0.75 | MEN1 (0.41) | NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221821-B2 | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds | Forest Laboratories Holdings, Limited (BM) | 2015-12-29 | — | — | US | disclosed |
| US-9221821-B2 | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds | Forest Laboratories Holdings, Limited (BM) | 2015-12-29 | — | — | US | disclosed |
| US-8501941-B2 | Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501941-B2 | Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501941-B2 | Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8420813-B2 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420813-B2 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420813-B2 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120226040-A1 | METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOAKYL SUBSTITUTED XANTHINES | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120226040-A1 | METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOAKYL SUBSTITUTED XANTHINES | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-7598379-B2 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598379-B2 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598379-B2 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070105821-A1 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | ALLERGAN SALES, LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070105821-A1 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | ALLERGAN SALES, LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070105821-A1 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | ALLERGAN SALES, LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
| WO-2006091936-A2 | METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOALKYL SUBSTITUTED XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | EEF2K 2793/4885CTSK 1910/4885TDP1 2304/4885 |
| US-20120226040-A1 | METHODS FOR THE SYNTHESIS OF UNSYMMETRICAL CYCLOAKYL SUBSTITUTED XANTHINES | ADORA2B, ADORA2A, ADORA3 | EEF2K 1679/4885CTSK 734/4885TDP1 2537/4885 |
| US-20070105821-A1 | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | EEF2K 2606/4885CTSK 1617/4885TDP1 2187/4885 |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADORA2B, GPR119, ADORA2A | EEF2K 1540/4885CTSK 1554/4885TDP1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.